

Cambridge University Press

978-1-107-07273-2 - Trade, Investment, Innovation and their Impact on Access to Medicines:
An Asian Perspective

Locknie Hsu

Index

[More information](#)

INDEX

- access to medicine. *See also* legal and policy constructs
 through advance market commitments, 342
 aging populations and, 3, 4–6
 through alliances and collaborations, 432–435
 ASEAN and, xxii, 32–41, 423–424, 425–426, 427–428
 under Bali Concord III, 425–426
 through biologics, 405–408
 through biosimilar products, 405–408
 in BRICS nations, 430–432
 business model changes and, 48–55
 businesses' role and, 352–353
 capacity-building as factor in, 435–436
 civil society's role in, 66
 competition law and, xxii
 data exclusivity protection and, 190–191
 data protection and, 353–366
 through data sharing and, 354–358
 domestic healthcare policies and, 38–41
 end user interests and, 64
 in EU, R&D collaborations for, 348
 FTAs and, 55–56, 72–77, 137–156, 157–158
 funding models for, 348–352
 future challenges for, 436–438
 through GIIN, 348
 global public health and, 29–32
 governmental influences on, 418–422
 governments' role and, 342–344
 through halal pharmaceuticals, 410–411
 through health funds and prizes, 339
 healthcare costs containment and, 65
 impact investing and, 348–350
 infrastructure and, 9
 innovative-incentive approach to patents and, 67–68
 innovator interests and, 64–65
 IPRs and, 338–339
 legal education as factor in, 435–436
 legal policies for, 26–27
 marketing approval costs reduction for, 424
 MPP and, 339, 340–342, 411
 multilateral trade and treaties and, 389–404
 new incentives for, 404–405
 new paradigms and strategies for, 334–337
 through non-adversarial problem-solving, 434–435
 non-profit organizations as influence on, 66
 non-treaty initiatives for, 339–342
 Novartis initiatives, 404
 through patent law, strengthening of, 418–420
 patent law and, 68–72
 through patentability standards, 418–420
 through personalized medicines, 408
 pharmaceutical industry and, 352–353, 411–418
 code of conduct guidelines for, 413–414
 corruption in supply chains as influence on, 420–422
 patents for, 68–72
 regulation of, 62–66
 soft rules for, 412–418
 through pharmaceutical initiatives, 422–430

- access to medicine (cont.)
 - pharmaceutical patents and, 68–72
 - PPPs for, 344–348
 - procurement agreements and, 88–90
 - regional healthcare priorities and, 32–41
 - through regional integration, 422–430
 - role of international organizations in, 27–29
 - scientific advances and, 26–27
 - through SIBs, 348–349
 - in Singapore, ecosystem for, 345–347
 - social policy strategies for, 26–27
 - sovereign wealth funds and, 415–416, 417
 - state interests and, 65
 - through traditional medicines, 408–409
 - treaty-based approaches to, 366–377
 - TRIPS and, 24–26
 - in U.S., R&D collaborations for, 348
 - through voluntary licensing, 433
 - through voluntary licensing arrangements, 340–342
 - whole-of-government approach to, 373–376
- Access to Medicines Index*, 50, 411–412
- active pharmaceutical ingredients (APIs), 17, 97
- advance market commitments, 342
- AEC. *See* ASEAN Economic Community
- AFTA. *See* ASEAN Free Trade Area
- aging populations
 - in Asia, 3, 4–6
 - life expectancy and, 5
 - in Singapore, 3, 4–6
- ALRC. *See* Australian Law Reform Commission
- anti-competition
 - compulsory licensing as remedy against, 259–260
 - in FTAs, provisions for, 287
 - in Singapore, 329–330
 - in TRIPS, 259–260
- Antimonopoly Law, 322–323
- anti-retroviral (ARV) drugs, 16
 - ASEAN and, access strategies of, 36–37
 - competition law and, 299
 - in South Africa, 299
- anti-trust law, 289–290. *See also* competition law
- APIs. *See* active pharmaceutical ingredients
- approval systems, for drugs and medicines
 - in ASEAN countries, 139
 - length of time in, 96–97
 - in non-ASEAN countries, 140
 - patent linkage and, 137–143
- ARV drugs. *See* anti-retroviral drugs
- ASEAN. *See* Association of Southeast Asian Nations
- ASEAN Economic Community (AEC), 2
- ASEAN Free Trade Area (AFTA), 2
- Asia. *See also* medicines, in Asia; *specific countries*
 - aging populations in, 3, 4–6
 - biosimilar products in, 406–407
 - biotechnology patents in, 117–127
 - Bolar exception in, 234–238
 - cancer incidences in, 8
 - chronic disease in, 7–8
 - communicable diseases in, 6–7
 - competition law in, 306–334
 - compulsory licensing in, 244, 254–260, 396–397
 - data exclusivity protection in, 146–156
 - data exclusivity protection throughout, 188–191
 - economic integration activities in, 22–23
 - economic reform in, 41–44
 - economic treaty exceptions and examples, 226
 - FTAs in, xxi, 2–3, 55–56, 167–168, 223
 - data exclusivity protections in, 188–191
 - patentability provisions in, 173–174
 - global pharmaceutical industry and, 48–55

Cambridge University Press

978-1-107-07273-2 - Trade, Investment, Innovation and their Impact on Access to Medicines:
An Asian Perspective

Locknie Hsu

Index

[More information](#)

INDEX

441

- globalization as economic influence
 - on, 1–3
- health care challenges in, 4–6
- health care costs in, 3, 12
- Hepatitis C in, 7
- HIV/AIDS in, 6–7
- IPRs in, 41–44
- ISDS system in, 202–203
- life expectancy in, 5
- malaria in, 7
- national health expenditures
 - throughout, 9–16
- patent term extensions in, 157–158, 161–162
- patentability of biotechnology in, 108–109, 117–127
- pay-for-delay agreements in, 297–298
- pharmaceutical expenses in, 9–11
- pharmaceutical industry in, 48–55
 - anticompetitive conduct and, 326–330
 - for ASEAN, 307–316, 325–326
 - competition law and, 306–334
 - compulsory licensing and, 326–330
 - corruption in, 88–90
 - counterfeit pharmaceuticals and, 97–99
 - drug price-control systems for, 90–94
 - generic substitution policies, 95
 - GST and, 85–88
 - marketing approval time in, 96–97
 - national pricing for, 85–88, 90–94
 - GST for, 85–88
 - patent linkage and, 331–332
 - procurement agreements in, 88–90
 - tariffs for, 83–84, 85
 - taxes and charges for, 85–88
 - user attitudes within, 96
- poverty in, 8–9
- public use licensing in, 396–397
- R&D in, 13–15
- TIFA and, 2–3
- TPP Agreement and, 23
- TRIPS and, xxi
- tuberculosis in, 7
- U.S. economic interest in, 2–3
- Association for Molecular Pathology et al v Myriad Genetics Inc et al*, 110–111
- Association of Southeast Asian Nations (ASEAN). *See also specific member nations*
- access to medicine influenced by, xxii, 32–41, 423–424, 425–426, 427–428
- AEC, 2
- AFTA, 2
- ARV access and, strategies for, 36–37
- Bali Concord III, 425–426
- Bali Concord III* and, 103
- barriers, 423–424
- data exclusivity protection for, 148–149
- data sharing and, regional integration through, 428–429
- domestic health policies and trade in medicine, 38–41
- exhaustion of patent rights in, 161–162
- FTAs and, 2–3
- halal pharmaceuticals in, 410–411
- HIV/AIDS integration strategies, 425–426
- IPRs and, strategies for, 36, 43–44
- ISDS claims against, 212, 213
- junctures of opportunity for, 426–427
- legal and policy constructs and, 103
- marketing approval cost reductions in, 424
- patent term extensions for, 157, 161–162
- pharmaceutical approval systems in, 139
- pharmaceutical industry and
 - generic substitution policies for, 95
 - GST for, 85–88
 - national pricing for, 85–88, 90–94
 - tariffs for, 83–84, 85
 - taxes and charges for, 85–88
- pharmaceutical production and, 18–21

Cambridge University Press

978-1-107-07273-2 - Trade, Investment, Innovation and their Impact on Access to Medicines:
An Asian Perspective

Locknie Hsu

Index

[More information](#)

442

INDEX

- Association of Southeast Asian (cont.)
 - public health and, 427–428
 - RCEP and, 3
 - regional healthcare systems and, 32–41
 - TIFA and, 2–3
- AstraZeneca AB v Ranbaxy (Malaysia) Sdn Bhd*, 143
- AstraZeneca AB (SE) v Sanofis-Aventis Singapore Pte LTD*, 141–143
- AstraZeneca v Commission*, 295–296
- Australia
 - ALRC in, 301
 - BRCA litigation, 111–113
 - competition law in, 300–301
 - ISDS system in, 203, 278
 - patent law in, 56–57
 - patentability in, 111–113
- Australia Patents Act, 111–113
- Australian Law Reform Commission (ALRC), 301
- Bali Concord III, 425–426
- Bali Concord III*, 103
- Bayer Corporation v NATCO Pharma Ltd.* in, 246–248
- Bercero, Ignacio Garcia, 216–217
- Bilateral Investment Promotion and Protection Agreement (BIPA), India, 206, 278–279
- bilateral investment treaties (BITs), 26
- Bilateral Trade Agreement (BTA), U.S. and Vietnam, 257
- Biogen Inc v Medeva plc*, 104–105
- biologics, 405–408
- biosimilar products, 405–408
- biotechnology patents, 105. *See also* patentability
 - approval systems for, 137–143
 - in Asia, 117–127
 - in China, 125
 - data exclusivity protection for, 143–156
 - development of, 106–117
 - divergent approaches to, 117–127
 - evergreening approach to, 127
 - in India, 125–126
 - in Indonesia, 124
 - in Korea, 126–127
 - in Malaysia, 123–124
 - for new and secondary uses of compounds, 127–137
 - new uses of, 127–137
 - patent linkage as factor for, 137–143
 - in the Philippines, 124
 - in Singapore, 118–123
 - term extensions for, 156–158
 - in Thailand, 124
 - in Vietnam, 125
- BIPA. *See* Bilateral Investment Promotion and Protection Agreement
- BITs. *See* bilateral investment treaties
- blockbuster drugs, 48–49
 - expiration of patents for, 49
- Bolar exception, in TRIPS, 59, 229–238
 - in Asia, 234–238
 - in Canada, 230–231
 - in EU, 233
 - in R&D, 234–238
 - Roche Products v Bolar Pharmaceutical Co* and, 229–230, 231
- brand-name medicines, 16
- Brazil
 - compulsory licensing in, 245–246
 - non-working patents in, 245–246
 - TRIPS Agreement and, 165
- Brenner v Manson*, 70
- BRICS nations, public health in, 430–432. *See also* Brazil; China; India; South Africa
- Brunei Darussalam
 - halal pharmaceuticals in, 410–411
 - TIFAs with, 2–3
- BTA. *See* Bilateral Trade Agreement
- Bush, George W., 2–3
- Cambodia
 - IPRs in, 238
 - patent law in, xxii, 42
 - pharmaceutical production in, 18
 - TIFAs with, 2–3
- Canada
 - Bolar exception in, 230–231
 - CETA and, 179

Cambridge University Press

978-1-107-07273-2 - Trade, Investment, Innovation and their Impact on Access to Medicines:
An Asian Perspective

Locknie Hsu

Index

[More information](#)

INDEX

443

- competition law in, 301–302
- Eli Lilly v Government of Canada*, 78, 208–211
- FTAs with Korea, 301–302
- IPRs in, 369–370
- ISDS system in, 203, 208–211
- patentability in, 116–117
- royalty rates in, 400–401
- TRIPS Agreement and, 165
- Canada (Commissioner of Patents) v Harvard College*, 116–117
- Canada-EU Comprehensive Economic and Trade Agreement (CETA), 179
- Canadian Intellectual Property Office (CIPO), 370
- cancer
 - access to medicines for, 404
 - in Asian populations, 8
- CETA. *See* Canada-EU Comprehensive Economic and Trade Agreement
- China. *See also* Association of Southeast Asian Nations
 - Antimonopoly Law in, 322–323
 - APIs in, 17
 - biotechnology patents in, 125
 - chronic disease in, 8
 - competition law in, 322–323
 - compulsory licensing in, 249–251
 - corruption issues in, 88–89
 - drug price controls in, 90–91
 - essential facilities, 322–323
 - FTAs in, 167–168
 - IPRs in, 322–323
 - new and secondary uses of drug compounds in, 135
 - non-working patents in, 249–251
 - patentability in, 125
 - pharmaceutical production in, 19
 - price caps in, for drugs and medicines, 420
 - procurement agreements in, 89–90
 - in WTO, 1
- Chinese Taipei, 52, 256–257
- chronic disease
 - in Asia, 7–8
 - in China, 8
- CIPO. *See* Canadian Intellectual Property Office
- civil society, access to medicine influenced by, 66
- clinical tests data, 143–156, 303–305, 317–318, 333, 353–366
- Coartem, 356
- coherence, IPRs, trade, investment, innovation, public health and, 339
- Common Market for Eastern and Southern Africa (COMESA) investment agreement, 271–273
- communicable diseases, 6–7. *See also* Hepatitis C; HIV/AIDS
- competition, within pharmaceutical industry, 62–64
- competition law
 - access to medicine and, xxii
 - ARV drugs and, 299
 - AstraZeneca v Commission* and, 295–296
 - in Australia, 300–301
 - in Canada, 301–302
 - in China, 322–323
 - essential facilities doctrine and, 303–305, 316–318, 333
 - in EU, 294–296
 - FTAs and, 306–307
 - FTC v Actavis* and, 291–293
 - generic drugs and, 290
 - in Hong Kong, 323–324
 - in India, 324–325, 328–329
 - IPRs and, 286–289
 - in Japan, 324
 - in Lao PDR, 307–308
 - in Malaysia, 308–309
 - objectives of, 286–287
 - patent law and, 285
 - pay-for-delay agreements and, 285
 - pharmaceutical industry and, in Asia, 306–334
 - anticompetitive conduct and, 326–330
 - for ASEAN, 307–316, 325–326
 - compulsory licensing and, 326–330

Cambridge University Press

978-1-107-07273-2 - Trade, Investment, Innovation and their Impact on Access to Medicines:
An Asian Perspective

Locknie Hsu

Index

[More information](#)

444

INDEX

- competition law (cont.)
 - patent linkage and, 331–332
 - in the Philippines, 308
 - refusal of licenses for patents and, 302–303
 - reverse-payment settlement agreements and, 285
 - in Singapore, 309–316, 318
 - in South Africa, 298–300
 - in Thailand, 320
 - in U.S., 289–294, 316
 - in Vietnam, 321–322
- compulsory licensing
 - in Asia, 244, 254–260, 396–397
 - in *Bayer Corporation v NATCO Pharma Ltd.*, 246–248
 - in Brazil, 245–246
 - in China, 249–251
 - to combat anti-competitive conduct, 259–260
 - in COMESA investment agreement, 271–273
 - in EU, 251
 - for FTAs, 243–252
 - government use, 396–397, 402–403
 - in India, 246–249, 255, 327, 400
 - in Indonesia, 255, 399–400
 - in Malaysia, 255
 - national provisions for, 244
 - non-working of patents and, 244–252
 - under Paris Convention, 243
 - for pharmaceutical patents, 60
 - in Singapore, 256–257, 312, 327, 329, 330–331
 - in Taiwan, 255
 - in Thailand, 62, 255, 257–259, 399–400
 - under TRIPS, 60, 243–252, 402–403
- constitutional rights to health in Asia, 38–41
- consumers, in pharmaceutical industry, 62–64
- copyrights. *See also* intellectual property rights
 - data sharing and, 357–358
 - societal benefits of, 357–358
- corruption, in pharmaceutical industry
 - access to medicine influenced by, 420–422
 - in Asian region, 88–90
 - in China, 88–89
 - in Thailand, 421
 - in Vietnam, 88–89
- counterfeit pharmaceuticals
 - APIs in, 97
 - in Asia, 97–99
 - distinguishing generic medicines from, 98–99
 - generic medicines compared to, 98–99
- Critical Path Initiative (C-Path Initiative), 348
- data exclusivity protection, for patents
 - access to medicines and, 190–191, 353–366
 - in ASEAN countries, 148–149
 - in Asian region, 146–156, 188–191
 - in biotechnology patents, 143–156
 - under EU law, 188
 - in EUSFTA, 196–197
 - in FTAs, 186–197, 260–263
 - Hatch-Waxman amendments and, 193
 - Singapore and, 193, 429–430
 - in Israel, 191–192
 - in Malaysia, 146–154
 - under NAFTA, 143, 186–187
 - in non-ASEAN countries, 152
 - patentability and, 143–156
 - in Singapore, 192–196
 - TRIPS Agreement and, 260–263
 - under U.S. law, 187–188
- data sharing, for drugs and medicines
 - access to medicine through, 354–358
 - ASEAN and, regional integration of, 428–429
 - copyrights and, 357–358
 - in EU, 362–365
 - new paradigm shifts for, 359–361
 - NITD and, 356
 - through open source systems, 358–359, 361
 - in pharmaceutical industry, 354–358

Cambridge University Press

978-1-107-07273-2 - Trade, Investment, Innovation and their Impact on Access to Medicines:
An Asian Perspective

Locknie Hsu

Index

[More information](#)

INDEX

445

- through public funds, 365–366
- developing countries
 - patents in, 104–105
 - tiered pricing systems in, for drugs and medicines, 385–387
- Diamond v Chakrabarty*, 110
- differential pricing, 377–378. *See also*
 - tiered pricing, for drugs and medicines
- disease. *See* chronic disease; communicable diseases
- dispute resolution, 387
- Doctors Without Borders. *See* Medics Sans Frontières
- Doha Declaration, 256–257, 338
- domestic healthcare systems
 - access to medicine in, 38–41
 - ASEAN and, 38–41
- Drug Price Competition and Patent Term Restoration Act, 291
- drug research programmes, 366
- drugs and medicines. *See also* approval systems, for drugs and medicines; generic drugs and medicines; medicines, in Asia; pricing, for drugs and medicines
 - biologics, 405–408
 - biosimilar products, 405–408
 - data sharing for
 - access to medicine through, 354–358
 - copyrights and, 357–358
 - in EU, 362–365
 - new paradigm shifts for, 359–361
 - NITD and, 356
 - through open source systems, 358–359, 361
 - in pharmaceutical industry, 354–358
 - through public funds, 365–366
 - for Hepatitis C, pricing strategies for, 379–381
 - herbal, 409
 - new and secondary uses for
 - biotechnology patents for, 127–137
 - in China, 135
 - in FTAs, 174–176
 - in India, 129–134
 - patentability of, 127–137
 - in Singapore, 135–137
 - in Thailand, 134–135
 - parallel imports of, 159–162
- EBD. *See* Economic Development Board
- economic development, globalization as influence on, 46–48
- Economic Development Board (EBD), 350
- economic reforms
 - in Asia, 41–44
 - in Myanmar, 2
- economic treaties. *See* multilateral trade and treaties; treaties, economic
- Egypt, pricing for drugs and medicines in, 379–381
- Eli Lilly v Government of Canada*, 78, 208–211
- EMA. *See* European Medicines Agency
- EML. *See* Essential Medicines List
- essential facilities doctrine, 303–305, 316–317
 - China, 305
 - competition law and, 317–318, 333
 - refusals to license, incipient linkages, 303–305
- Essential Medicines List (EML), 11, 28
- EU. *See* European Union
- European Medicines Agency (EMA), 390–391
- European Union (EU)
 - AstraZeneca v Commission* in, 295–296
 - Bolar exception in, 233
 - CETA and, 179
 - clinical data sharing scheme, 362–365
 - competition law in, 294–296
 - compulsory licensing in, 251
 - data exclusivity protection in, 188
 - data sharing in, 362–365
 - drug research programmes in, 366
 - EUSFTA, 184–186
 - FTAs and, 173

Cambridge University Press

978-1-107-07273-2 - Trade, Investment, Innovation and their Impact on Access to Medicines:
An Asian Perspective

Locknie Hsu

Index

[More information](#)

446

INDEX

- European Union (EU) (cont.)
 - HiAP approach in, 374–376
 - IMI, 348
 - incentives for innovation in, 343–344
 - non-working patents in, 251
 - patentability in, 111
 - pay-for-delay agreements in, 296
 - pharmaceutical sector inquiry
 - report, 56
 - increased competition law enforcement and, 294–296
 - R&D in, collaborations in, 348
 - tiered pricing systems in, 378, 385–387
 - TRIPS Agreement disputes, 165–166
- EU-Singapore Free Trade Agreement (EUSFTA), 184–186
 - data exclusivity protection in, 196–197
- evergreening approach
 - in FTAs, 168, 240–241
 - to patents, 127
- exception provisions, in trade treaties
 - in Asian regions, 226
 - in FTAs, xix, 221–223, 241–242
 - in future treaties, 279–280
 - General Saving of National Law, 241–242
 - in investment treaties, 268–273
 - for IPRs, 228–229
 - MFN treatment to, 266
 - non-violation provisions for, 266–267
 - safe harbours provisions, 225–227
 - security exceptions, 273–274
 - in TRIPS Agreement, 228–238
 - in USSFTA, 226–227
- exhaustion of rights, in FTAs, 242
- expropriation
 - in investment treaties, 268–273
 - in ISDS systems, 206–207
- external reference pricing, 382–383
- Fair and equitable treatment, ISDS
 - system and, 204–206
- First Currency Choice Pte Ltd v Main-Line Corporate Holdings Ltd*, 70–71
- formulary systems, in FTAs, 182–186
- free trade agreements (FTAs). *See also* General Agreement on Trade and Tariffs
 - anti-competition provisions in, 287
 - ASEAN and, 2–3
 - in Asia, xxi, 2–3, 55–56, 167–168, 223
 - data exclusivity protections in, 188–191
 - patentability provisions for, 173–174
 - Asian approach to, xxi
 - BIPA, 206
 - in China, 167–168
 - competition law and, 306–307
 - compulsory licensing for, 243–252
 - data exclusivity provisions in, 186–197, 260–263
 - dispute resolution provisions in, 387
 - ethical business practices and, 215
 - between EU and India, 173
 - EUSFTA, 184–186
 - evergreening in, 168, 240–241
 - exception provisions in, xix, 221–223, 241–242
 - exhaustion of rights in, 242
 - foreign policy measures in, 274–275
 - GATT and, 168–169
 - General Saving of National Law
 - exceptions in, 241–242
 - government policy-making as influence on, 429–430
 - health provisions, 23
 - impairment of, 266
 - India and, 3
 - investment factors in, 23
 - investment interests as part of, 169–172
 - investment treaties and, 268–273
 - in Israel, 191–192
 - between Korea and Canada, 369–370
 - KORUS, 182–183, 197–198, 226–227
 - Malaysia and, 171
 - MFN basis in, 219
 - NAFTA, 143, 186–187, 208–211
 - national formulary systems and, 182–186
 - negotiation options for, 280–281

- new and secondary uses of drug compounds in, 174–176
- nullification of, 266
- objectives in, 227–228
- parallel imports in, limitations of, 180–181
- patent bargain and, 71–77
- patent linkage provisions in, 197–200, 262–263
- patent opposition limitations in, 180
- patent term extensions in, 176–179
- patentability as aspect of, 172–176, 238–242
- public health and, 169–172, 264–265, 371–373
- regulatory provisions in, 214–215
- reimbursement systems and, 182–186
- renewal of patents under, 180
- revocation of patents under, 180
- RTAs and, 168–169
- scope of, 168–169
- security exceptions in, 273–274
- Singapore and, 2–3, 169–170, 173–174
- TPP and, 171–172
- trade factors in, 23
- trade interests as part of, 169–172
- treaty protections for, 80
- TRIPS-plus provisions, 219, 220–221
- USSFTA, 173–174, 177–179, 198–200, 226–227
- Free Trade Area of the Asia Pacific (FTAAP), 436–438
- free-riding, 82
- FTAAP. *See* Free Trade Area of the Asia Pacific
- FTAs. *See* Free Trade Agreements
- FTC v Actavis*, 291–293
- funding. *See also* health funds and prizes
 - for access to medicine, models for, 348–352
 - for data sharing, 365–366
 - Global Funds for AIDS, Tuberculosis and Malaria, 339
 - IFAD, 8
 - MAF, 13–15
 - SWFs, 350–352
- General Agreement on Trade and Tariffs (GATT), 168–169, 212
 - exception provisions in, 221–223
 - negotiation options for, 280–281
 - non-violation provisions in, 266–267
- General Saving of National Law exceptions, 241–242
- Generic Drugs Act, 39–40
- generic drugs and medicines, 16
 - Bolar exception and, 59, 229–238
 - competition law and, 290
 - counterfeit pharmaceuticals compared to, 98–99
 - ISDS systems and, 211
 - legal and policy constructs for, 102
 - substitution policies for, 95
- genes, gene sequences and BRCA, 109
 - patentability of, 109
- GIIN. *See* Global Impact Investing Network
- Gilead Sciences, 379–381
- Glaxo Wellcome (Pty) Ltd & Others v National Association of Pharmaceutical Wholesalers & Others*, 298–300
- GlaxoSmithKline, 50
- Global Funds for AIDS, Tuberculosis and Malaria, 339
- Global Impact Investing Network (GIIN), 348
- Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPOA), 335–336
- globalization
 - Asia influenced by, 1–3
 - economic development influenced by, 46–48
 - public health dimensions of, 46–56
- good manufacturing practices (GMPs), 18
- Goods & Services Tax (GST), 85–88
- GSPOA. *See* Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property
- GST. *See* Goods & Services Tax

Cambridge University Press

978-1-107-07273-2 - Trade, Investment, Innovation and their Impact on Access to Medicines:
An Asian Perspective

Locknie Hsu

Index

[More information](#)

448

INDEX

- halal pharmaceuticals, 410–411
- Hatch-Waxman amendments, 193.
 - See also* Drug Price Competition and Patent Term Restoration Act
- Hazel Tau and Others vs GlaxoSmithKline and Boehringer Ingelheim*, 299
- health care costs. *See also* health expenditures, national
 - in Asia, 3, 12
 - containment of, access to medicine influenced by, 65
 - out-of-pocket, 9
- health expenditures, national
 - for pharmaceutical expenses, 9–11
 - in Singapore, 11–16
 - throughout Asia, 9–16
- health funds and prizes, 339
 - Medical Innovation Prize Fund Act, 340
- Health in All Policies (HiAP) approach, 374–376
- Health Sciences Authority (HSA), 193, 199
- Health Technology Assessment (HTA), 376–377
- healthcare systems
 - globalization as influence on, 46–56
 - in Singapore, public financing of, 13–15
 - social policy strategies for, 26–27
- Hepatitis C
 - in Asia, 7
 - drugs and medicine for, pricing strategies for, 379–381
- herbal medicines, 409
- HiAP approach. *See* Health in All Policies approach
- HIV/AIDS
 - ASEAN integration strategies, 425–426
 - in Asia, 6–7
 - Global Funds for AIDS, Tuberculosis and Malaria, 339
 - pricing for drugs for, 381
- Hong Kong
 - competition law in, 323–324
 - procurement agreements in, 89–90
- HSA. *See* Health Sciences Authority
- HTA. *See* Health Technology Assessment
- Human Genome Sciences Inc v Eli Lilly Company*, 69–70, 115, 284
- IFAD. *See* International Fund for Agricultural Development
- IMI. *See* Innovative Medicines Initiative
- incentives, for innovation
 - for access to medicine, state's role in, 67–68, 342–344
 - in EU, 343–344
 - Patents for Humanity programme, 343–344
 - in U.S., 343–344
- India. *See also* Association of Southeast Asian Nations
 - APIs in, 17
 - Bayer Corporation v NATCO Pharma Ltd.* in, 246–248
 - biotechnology in, 125–126
 - BIPA in, 206, 278–279
 - competition law in, 324–325, 328–329
 - compulsory licensing in, 246–249, 255, 327, 400
 - draft model investment treaty, 203, 206, 278–279
 - drug price controls in, 91–92
 - FTAs and, 3, 173
 - halal pharmaceuticals in, 410–411
 - IPRs in, 236
 - new and secondary uses of drug compounds in, 129–134
 - non-profit organizations in, 66
 - non-working of patents in, 246–249
 - Novartis AG v Union of India*, 129–134
 - open source systems, 361
 - patent law in, 43
 - patentability in, 125–126, 241
 - pricing for drugs and medicines in, 383

Cambridge University Press

978-1-107-07273-2 - Trade, Investment, Innovation and their Impact on Access to Medicines:
An Asian Perspective

Locknie Hsu

Index

[More information](#)

INDEX

449

- procurement agreements in, 89–90
- TRIPS Agreement disputes, 165–166
- Indonesia
 - biotechnology patents in, 124
 - compulsory licensing in, 255, 399–400
 - drug price controls in, 93
 - IPRs in, 237–238
 - patentability in, 124
 - pharmaceutical production in, 18
 - procurement agreements in, 89–90
 - TIFAs with, 2–3
- innovation, innovators and
 - access to medicine and, 64–65, 339
 - coherence strategies for, access to medicines and, 339
 - C-Path Initiative, 348
 - free-riding on, 82
 - IMI and, 348
 - incentive theory and, 67–68, 342–344
 - interests of, 64–65
 - patent bargain and, 72, 79–80
 - in pharmaceutical industry, 51–55, 62–64
 - policy development for, 283–286
 - PPPs for, 344–348
 - in Singapore, 345–347
 - whole-of-government approach to, 373–376
- innovation mercantilism, 82
- Innovative Medicines Initiative (IMI), 348
- Intellectual Property Office of Singapore (IPOS), 118–123
 - patentability, 118–123
 - public morals, 121
- intellectual property rights (IPRs). *See also* data exclusivity
 - protection, for patents
 - access to medicines and, 338–339
 - ASEAN and, strategies for, 36, 43–44
 - in Asia, 41–44
 - in Cambodia, 238
 - in Canada, 369–370
 - in China, 322–323
 - competition law and, 286–289
 - essential facilities doctrine and, 303–305, 316–317
 - exhaustion of, 159–162
 - in India, 236
 - in Indonesia, 237–238
 - ISDS systems and, 201–212
 - in Japan, 304
 - in Korea, 369–370
 - in Myanmar, 43
 - objectives of, 286–287
 - in the Philippines, 237
 - protectionist agenda for, in developed countries, 81, 82
 - reform strategies for, 301
 - shifts in, xvii
 - in Singapore, 118–123, 235–236, 310–311
 - in Thailand, 235
 - in TRIPS, exceptions to, 228–229
 - TRIPS and, xvii–xviii, 58–61
 - in U.S., 220–221
 - in Vietnam, 235
- International Fund for Agricultural Development (IFAD), 8
- investment treaties
 - COMESA investment agreement, 271–273
 - exception provisions in, relevant to health, 268–273
 - expropriation provisions in, relevant to health, 268–273
 - FTAs and, 268–273
- investor-State dispute settlement (ISDS) system, 26
 - ASEAN and, claims against, 212, 213
 - in Asia, 202–203
 - in Australia, 203, 278
 - BIPA and, 206
 - in Canada, 203, 208–211
 - criticisms of, 211
 - damage sums through, 211–212
 - Eli Lilly v Government of Canada* and, 208–211
 - expropriation issues in, 206–207
 - FET and, 204–206
 - generic medicines and, 211
 - investment provisions in, 204–206
 - IPRs and, 201–212

Cambridge University Press

978-1-107-07273-2 - Trade, Investment, Innovation and their Impact on Access to Medicines:
An Asian Perspective

Locknie Hsu

Index

[More information](#)

450

INDEX

- investor-State dispute (cont.)
 in Latin America, 201–202
 legal risks and concerns in, 201–214
 NAFTA and, 208–211
 patent bargain and, 212–214
 pharmaceutical patents and,
 208–211
 scope of, 201–212
 security exceptions in, 273
 TTIP and, 216–217
- IPOS. *See* Intellectual Property Office of
 Singapore
- IPRs. *See* intellectual property rights
- ISDS. *See* investor-State dispute
 settlement system
- Israel
 data exclusivity protection in,
 191–192
 FTAs in, 191–192
- Japan
 APIs in, 17
 competition law in, 324
 IPRs in, 304
 JSEPA, 227
 procurement agreements in, 89–90
 refusal of licenses for patents in, 304
- Japan-Singapore Economic Partnership
 Agreement (JSEPA), 227
- KFTC. *See* Korean Fair Trade
 Commission
- Korea. *See also* Association of Southeast
 Asian Nations
 APIs in, 17
 biotechnology in, 126–127
 drug price controls in, 92–93
 FTAs with Canada, 369–370
 IPRs in, 369–370
 KFTC v GSK/Dong-A, 297–298
 KORUS FTA, 182–183, 197–198,
 226–227
 non-profit organizations in, 66
 Ombudsman, 387
 patentability in, 126–127
 pay-for-delay agreements in,
 297–298
 procurement agreements in, 89–90
- Korean Fair Trade Commission
 (KFTC), 297–298
- Korean Patent Act, 126–127
- Korea-U.S. Free Trade Agreement
 (KORUS FTA), 182–183
 exception provisions in, 226–227
 formulary, 182–183
 patent linkage provisions in,
 197–198
- Lao PDR
 competition law in, 307–308
 compliance with TRIPS, 42
 patent law in, xxii
 pharmaceutical production in, 18
 poverty in, 9
- Latin America, ISDS systems in,
 201–202
- law
 access to medicine and, 26–27
 scientific advances in medicine and,
 26–27
- legal and policy constructs. *See also*
 patent law
 ASEAN and, 103
 for generic medicines, 102
 for patentability, 104–105
 for trade and investment in
 medicines, 101–102
- licensing. *See* compulsory licensing;
 public use licensing; refusal
 of licenses; voluntary
 licensing
- life expectancy, in Asia, 5
- Lincoln, Abraham, 68
- local medical traditions. *See* traditional
 medicines
- MAF. *See* Medication Assistance Fund
- malaria
 in Asia, 7
 Global Funds for AIDS, Tuberculosis
 and Malaria, 339
 Mozambique Malaria Performance
 Bond, 350
- Malaysia
 AstraZeneca AB v Ranbaxy
 (Malaysia) Sdn Bhd in, 143

Cambridge University Press

978-1-107-07273-2 - Trade, Investment, Innovation and their Impact on Access to Medicines:
An Asian Perspective

Locknie Hsu

Index

[More information](#)

INDEX

451

- biotechnology patents in, 123–124
- competition law in, 308–309
- compulsory licensing in, 255
- data exclusivity protection in, 146–154
- FTAs and, 171
- GST in, 85–88
- halal pharmaceuticals in, 410–411
- patent linkage in, 141
- patentability in, 123–124
- pharmaceutical industry in, 85–88
- pharmaceutical production in, 18, 20–21
- procurement agreements in, 89–90
- TIFAs with, 2–3
- Mandelson, Peter, 258
- Mayo Collaborative Services and Mayo Medical Laboratories et al v Prometheus Inc*, 110
- Medical Innovation Prize Fund Act, 340
- Medication Assistance Fund (MAF), 13–15
- medicines, in Asia. *See also* access to medicine; approval systems, for drugs and medicines; generic drugs and medicines; legal and policy constructs; pricing, for drugs and medicines; scientific advances, for medicine
 - APIs in, 17
 - ARV drugs, 16
 - brand-name, 16
 - EML, 11
 - MAF for, 13–15
 - parallel imports of, 159–162
 - pricing for, 17–18
 - R&D for, 13–15
 - on SDL, 13–15
 - traditional, 21–22
- Medicines Act, 194–196
- Medicines Patent Pool (MPP), 339, 340–342, 411
- Medicins Sans Frontières (Doctors Without Borders), 66
- Mexico, access to medicine in, 413–414
- MFN. *See* most-favoured nations
- migrant workers, public health for, 428
- Millennium Development Goals (MDGs), 30
- Minister for Trade and Industry (MTI), 169–170
- Mongolia, procurement agreements in, 89–90
- most-favoured nations (MFN), 219, 266
- Mozambique Malaria Performance Bond, 350
- MPP. *See* Medicines Patent Pool
- MTI. *See* Minister for Trade and Industry
- multilateral trade and treaties. *See also specific treaties*
 - access to medicines influenced by, 389–404
 - for public health, 366–367
 - for R&D, 366–367
- Murray, Kali, 68
- Myanmar
 - drug price controls in, 93
 - economic reforms in, 2
 - in GATT, 212
 - IPRs in, 43
 - patent law in, xxii
 - regional healthcare systems in, 40–41
 - TIFAs with, 2–3
- NAFTA. *See* North American Free Trade Agreement
- National Essential Medicines System (NEMS), 11
- national health expenditures. *See* health expenditures, national
- NCEs. *See* new chemical entities
- neglected drugs, 67–68
- Neglected Tropical Disease, 7
- NEMS. *See* National Essential Medicines System
- the Netherlands, TRIPS Agreement and, 165
- new chemical entities (NCEs), 61
- NITD. *See* Novartis Institute for Tropical Diseases
- non-FTA mechanisms, international patent law and, 172

Cambridge University Press

978-1-107-07273-2 - Trade, Investment, Innovation and their Impact on Access to Medicines:
An Asian Perspective

Locknie Hsu

Index

[More information](#)

452

INDEX

- non-profit organizations
 - access to medicine influenced by, 66
 - in India, 66
 - in Korea, 66
 - in Thailand, 66
- non-violation provisions, 266–267
- non-working patents
 - in Brazil, 245–246
 - in China, 249–251
 - compulsory licensing and, 244–252
 - in EU, 251
 - in India, 246–249
- North American Free Trade Agreement (NAFTA)
 - data exclusivity protections under, 143, 186–187
 - ISDS systems and, 208–211
- Novartis, access to medicines
 - initiative, 404
- Novartis AG v Union of India*, 129–134
- Novartis Institute for Tropical Diseases (NITD), 356
- Occidental v Ecuador*, 211–212
- Open Source Drug Discovery (OSDD) Programme, 361
- open source systems, 358–359, 361
- organizations, international. *See also*
 - World Health Organization;
 - World Trade Organisation
- role in access to medicine, 27–29
- OSDD Programme. *See* Open Source Drug Discovery Programme
- Ottawa Charter for Health Promotion, 30
- out-of-pocket health care costs, in Asia, 9
- “Paragraph 6” mechanism, WTO, 250, 273, 327
- parallel imports
 - of drugs and medicines, 159–162
 - in FTAs, 180–181
 - international exhaustion and, ASEAN, 161–162
 - in Singapore, 180–181
 - tiered pricing and, EU system, 385–387
- Paris Convention, 243
- patent bargain, 68–72, 77–78
 - commercial practices and, 80
 - FTAs and, 71–77
 - innovation and, 72
 - innovator-incentive approach in, 79–80
 - ISDS system and, 212–214
 - negotiation trade-offs as part of, 79
 - rewards theory and, 72
 - social contract theory and, 72
 - state interests in, 79
 - “treatified”, 71–77
 - treaty protections and, 80
 - TRIPS Agreement and, 71–77, 162–163
 - WTO members and, 74–76
- Patent Cooperation Treaty, 52
- patent law. *See also* intellectual property rights
 - access to medicines and, 68–72, 418–420
 - in Australia, 56–57
 - Brenner v Manson* and, 70
 - in Cambodia, xxii, 42
 - competition law and, 285
 - Eli Lilly v Government of Canada* and, 78
 - in *First Currency Choice Pte Ltd v Main-Line Corporate Holdings Ltd*, 70–71
 - government reviews on, 56
 - in *Human Genome Sciences Inc v Eli Lilly Company*, 69–70
 - in India, 43
 - key elements of, 103–117
 - KFTC and, 297–298
 - in Lao PDR, xxii
 - in Myanmar, xxii
 - non-FTA mechanisms and, 172
 - quid pro quo* status in, 69
 - in *Teva Canada v Pfizer Canada*, 70
 - in Thailand, 62
 - under TRIPS, 25–26, 58–61
- patent linkage
 - approval systems and, 137–143
 - for biotechnology patents, 137–143
 - in FTAs, 197–200, 262–263

Cambridge University Press

978-1-107-07273-2 - Trade, Investment, Innovation and their Impact on Access to Medicines:
An Asian Perspective

Locknie Hsu

Index

[More information](#)

INDEX

453

- for generic competitors, 141–143
- judicial decisions of interest on, 141–143
- in KORUS FTA, 197–198
- in Malaysia, 141
- patentability and, 137–143
- in Singapore, 141–143
 - Medicines Act, 141–143
- patent term extensions, 156–158
 - in ASEAN countries, 157, 161–162
 - in Asian region, 157–158, 161–162
 - in FTAs, 176–179
 - in USSFTA, 177–179
- patentability
 - access to medicine and, 418–420
 - approval systems for, 137–143
 - in Asia, 108–109, 117–127
 - in Australia, 111–113
 - of biotechnology, 106–117
 - of BRCA genes, 109
 - in Canada, 116–117
 - in China, 125
 - data exclusivity protections and, 143–156
 - defined, 104–105
 - divergent approaches to, 117–127
 - in EU, 111
 - evergreening approach to, 127
 - FTAs and, 172–176, 238–242
 - as a gateway, 104
 - of genes and gene sequences, 109
 - in India, 125–126, 241
 - in Indonesia, 124
 - in Korea, 126–127
 - in Malaysia, 123–124
 - of new and secondary uses of compounds, 127–137
 - patent linkage as factor in, 137–143
 - in the Philippines, 124
 - regulatory issues for, 107–108
 - in Singapore, 118–123
 - in Thailand, 124
 - TRIPS Agreement and, 238–242
 - in U.K., 108, 115
 - in U.S., 108, 110–111
 - USSFTA and, 173–174
 - in Vietnam, 125
- patents, pharmaceutical, 66–80. *See also*
 - biotechnology patents;
 - competition law; data
 - exclusivity protection, for
 - patents; non-working patents
- access to medicines and, 68–72
- Brenner v Manson* and, 70
- commercial practices for, 80
- compulsory licensing for, 60
- in developing countries, 104–105
- Eli Lilly v Government of Canada* and, 78
- evergreening approach to, 127
- exhaustion of, 161–162
- First Currency Choice Pte Ltd v Main-Line Corporate Holdings Ltd* and, 70–71
- under FTAs, renewal and revocation of, 180
- in *Human Genome Sciences Inc v Eli Lilly Company*, 69–70
- innovative-incentive approach to, 67–68
- international commitments, 57–58
- ISDS system and, 208–211
- NCEs and, 61
- patentability, 104–105
- quid pro quo* status for, 69
- state interests in, 65
- submarine, 105
- Teva Canada v Pfizer Canada* and, 70
- treaty protections and, 80
- under TRIPS Agreement, 57–61
- Patents Act, 180–181
- Patents for Humanity programme, 343–344
- pay-for-delay agreements
 - in Asia, 297–298
 - in *AstraZeneca v Commission*, 295–296
- competition law and, 285
- in EU, 296
- in Korea, 297–298
- patent law and, 297–298
- in U.S., 293–294
- personalized medicines, 408

Cambridge University Press

978-1-107-07273-2 - Trade, Investment, Innovation and their Impact on Access to Medicines:
An Asian Perspective

Locknie Hsu

Index

[More information](#)

454

INDEX

- pharmaceutical expenses. *See also*
 patents, pharmaceutical
 in Asia, 9–11
 under EML, 11
 under NEMS, 11
- pharmaceutical industry. *See also*
 corruption, in pharmaceuti-
 cal industry; patents,
 pharmaceutical
 access to medicine and, 352–353,
 411–418
 code of conduct guidelines for,
 413–414
 corruption of supply chain as
 influence on, 420–422
 patents for, 68–72
 regulation of, 62–66
 Santiago Principles on sovereign
 wealth funds, 415–416, 417
 soft rules for, 412–418
- ASEAN and
 generic substitution policies
 for, 95
 GST for, 85–88
 national pricing for, 85–88, 90–94
 tariffs for, 83–84, 85
 taxes and charges for, 85–88
- in Asia, 48–55
 anticompetitive conduct and,
 326–330
 for ASEAN, 307–316, 325–326
 competition law and, 306–334
 compulsory licensing and,
 326–330
 corruption in, 88–90
 counterfeit pharmaceuticals and,
 97–99
 drug price-control systems for,
 90–94
 generic substitution policies, 95
 GST for, 85–88
 marketing approval time in, 96–97
 national pricing for, 85–88, 90–94
 patent linkage and, 331–332
 procurement agreements in,
 88–90
 tariffs for, 83–84, 85
 taxes and charges for, 85–88
 user attitudes within, 96
 blockbuster drugs, 48–49
 codes of conduct for, 412–418
 competition law and, 306–334
 competitors in, 62–64
 consumers in, 62–64
 corruption and, 420–422
 China, 88–90
 data sharing for, 354–358
 end user interests in, 64
 ethical issues, Korea-US FTA
 provisions on, 214–215
 FTAs and, 55–56
 government reviews on, 56
 innovation and innovators in, 51–55,
 62–64
 in Malaysia, 85–88
 new paradigms and strategies for,
 334–337
 parallel imports in, 159–162
 R&D in, 49–50
 regulation of, 62–66
 in Singapore, 85–88
 TRIPS Agreement and, 52–55,
 58–61
- pharmaceutical production
 APIs in, 17
 in ASEAN nations and, 18–21
 in China, 19
 GMP for, 18
 in Malaysia, 18, 20–21
 in Thailand, 18, 19–20
- Pharmaceutical Products Agreement,
 393–394
- the Philippines
 biotechnology patents in, 124
 competition law in, 308
 data exclusivity protection in,
 155–156
 drug price controls in, 93–94
 Generic Drugs Act in, 39–40
 IPRs in, 237
 patentability in, 124
 pharmaceutical production in, 18
 TIFAs with, 2–3
 Universally Cheaper and Quality
 Medicines Act in, 40, 155–156
- Plant Varieties Protection Act, 240

Cambridge University Press

978-1-107-07273-2 - Trade, Investment, Innovation and their Impact on Access to Medicines:
An Asian Perspective

Locknie Hsu

Index

[More information](#)

INDEX

455

- PMCPA. *See* Prescription Medicines Code of Practice Authority
- populations
- aging of, in Asia, 3, 4–6
 - estimated projections for, 5
- poverty
- in Asia, 8–9
 - Lao PDR in, 9
- PPPs. *See* public-private partnerships
- Precision Medicine Initiative, 408
- Prescription Medicines Code of Practice Authority (PMCPA), 413
- pricing, for drugs and medicines, 17–18
- in China, through price caps, 420
 - differential, 377–378
 - in Egypt, 379–381
 - external reference, 382–383
 - for Hepatitis C, 379–381
 - for HIV/AIDS, 381
 - in India, 383
 - negotiation strategies for, 379–381
 - for pharmaceutical industry, in Asia, 85–88
 - in China, 90–91
 - control systems in, 90–94
 - in India, 91–92
 - in Indonesia, 93
 - in Korea, 92–93
 - in Myanmar, 93
 - in the Philippines, 93–94
 - in Vietnam, 94
- for sofosbuvir, 379–381
- tiered, 377–387
- demand-side concerns for, 384
 - for developing countries, 385–387
 - disincentives for, 382
 - in EU, 378, 385–387
 - for global pharmaceutical companies, 379
 - supply-side concerns for, 382–384
 - sustainable frameworks for, 381
- procurement, corruption and, 88–90, 415, 420–422
- procurement agreements, 88–90
- public health
- ASEAN and, 427–428
 - in BRICS nations, 430–432
 - dispute resolution provisions for, 387
 - FTAs for, 169–172, 264–265, 371–373
 - health representatives in negotiation process, 370–371
 - HiAP approach to, 374–376
 - HTA for, 376–377
 - for migrant workers, 428
 - multilateral treaty for, 366–367
 - national agencies' role in, 370–371
 - trade and investment treaty and, 368–369
 - treaty-based approaches to, 366–367
 - whole-of-government approach to, 373–376
- Public Health Declaration, 252–254
- public morals and patentability, 418–420
- public use licensing, 396–397
- public-private partnerships (PPPs), 336–337
- C-Path Initiative, 348
- IMI and, 348
- for R&D, for public health promotion, 344–348
- RCEP. *See* Regional Comprehensive Economic Partnership
- R&D. *See* research and development
- refusal of licenses, for patents, 302–305
- competition law and, 302–303
 - essential facilities doctrine and, 303–305
 - in Japan, 304
- Regional Comprehensive Economic Partnership (RCEP), 3
- regional healthcare systems
- access to medicine in, 32–41
 - ASEAN role in, 32–41
 - in Myanmar, 40–41
 - RCEP and, 3
 - in Thailand, 41
 - in Vietnam, 40
- regional trade agreements (RTAs), 168–169
- reimbursement systems, in FTAs, 182–186
- research, new platform in, 432–435

- research and development (R&D). *See also* data sharing
 in Asia, for medicines, 13–15
 Bolar exception as factor in, 234–238
 in EU, 348, 366
 for medicines, in Asia, 13–15
 multilateral treaty for, 366–367
 paradigm changes for, 344–348
 in pharmaceutical industry, 49–50
 PPPs for, 344–348
 in Singapore, 345–347
 treaty-based approaches to, 366–377
 in U.S., 348, 366
- reverse-payment settlement
 agreements, competition law
 and, 285
- rewards theory, 72
- Roche Products v Bolar Pharmaceutical Co*, 229–230, 231
- royalty rates
 in Asian laws, 394–404
 in Canada, 400–401
 in TRIPS Agreement, 394–404
- RTAs. *See* regional trade agreements
- Sanders, Bernard, 340
- Santiago Principles on sovereign wealth funds, 415–416, 417
- scientific advances, for medicine
 legal policy and, 26–27
 social policy and, 26–27
- SDL. *See* Standard Drug List
- secondary uses of drug compounds. *See*
 new and secondary uses of
 drug compounds
- security exceptions
 in FTAs, 273–274
 in ISDS system, 273
- Shinawatra, Thaksin, 257
- SIBs. *See* social impact bonds
- Singapore
 aging populations in, 11–13
 anti-competitive conduct in,
 329–330
 APIs in, 17
 *AstraZeneca AB (SE) v Sanofis-
 Aventis Singapore Pte LTD* in,
 141–143
 biotechnology patents in, 118–123
 competition law in, 309–316, 318
 compulsory licensing in, 256–257,
 312, 327, 329, 330–331
 data exclusivity protection in, 192–196
 EBD in, 350
 ecosystem in, for access to medicine,
 345–347
 EUSFTA, 184–186
 FTAs and, 2–3, 169–170
 GST in, 85–88
 halal pharmaceuticals in, 410–411
 HSA in, 193, 199
 innovation in medicines in, 345–347
 IPOS in, 118–123
 IPRs in, 118–123, 235–236, 310–311
 JSEPA, 227
 MAF in, 13–15
 Medicines Act in, 194–196
 MTI in, 169–170
 national health expenditures in, 11–16
 new and secondary uses of drug
 compounds in, 135–137
 parallel imports limitations in
 expenditures in, 180–181
 patent linkage in, 141–143
 patentability in, 118–123
 Patents Act in, 180–181
 pharmaceutical industry in, 85–88
 pharmaceutical production in, 18
 procurement agreements in, 89–90
 public financing of healthcare system
 in, 13–15
 R&D in, for access to medicines,
 345–347
 SDL in, 13–15, 129
 USSFTA and, 173–174, 177–179,
 198–200, 226–227,
 262–263, 372
 Singapore Patents Act, 135–137
 social contract theory, 72
 social impact bonds (SIBs), 348–349
 sofosbuvir, 379–381
 South Africa, competition law in,
 298–300
 Sovaldi. *See* sofosbuvir
 sovereign wealth funds (SWFs),
 350–352, 415–416

Cambridge University Press

978-1-107-07273-2 - Trade, Investment, Innovation and their Impact on Access to Medicines:
An Asian Perspective

Locknie Hsu

Index

[More information](#)

INDEX

457

- Sri Lanka, procurement agreements in, 89–90
- Standard Drug List (SDL), 13–15, 129
- Strattera*, 208
- submarine patents, 105
- Sustainable Development Goals (SDGs), 31, 35, 437
- SWFs. *See* sovereign wealth funds
- Taiwan (Chinese Taipei), compulsory licensing in, 255
- tariffs, for pharmaceutical industry, in Asia, 83–84, 85
- taxes
- GST, in Malaysia and Singapore, 85–88
 - for pharmaceutical industry, in Asia, 85–88
- Teva Canada v Pfizer Canada*, 70
- Thailand
- APIs in, 17
 - ARV drugs in, 16
 - biotechnology patents in, 124
 - competition law in, 320
 - compulsory licensing in, 62, 255, 257–259, 399–400
 - halal pharmaceuticals in, 410–411
 - IPRs in, 235
 - new and secondary uses of drug compounds in, 134–135
 - non-profit organizations in, 66
 - patent law in, 62
 - patentability in, 124
 - pharmaceutical patent litigation in, 134–135
 - pharmaceutical production in, 18, 19–20
 - regional healthcare systems in, 41
 - TIFAs with, 2–3
- tiered pricing, for drugs and medicines, 377–387
- demand-side concerns for, 384
 - for developing countries, 385–387
 - disincentives for, 382
 - in EU, 378, 385–387
 - for global pharmaceutical companies, 379
 - supply-side concerns for, 382–384
 - sustainable frameworks for, 381
- TIFA. *See* Trade and Investment Framework Agreement
- TPP Agreement. *See* Trans-Pacific Partnership Agreement
- trade and investment, in medicines
- coherence strategies for, 339
 - FTAs for, 169–172
 - legal and policy constructs for, 101–102
 - negotiation options for, 280–281
 - for public health, 368–369
 - whole-of-government approach to, 373–376
- Trade and Investment Framework Agreement (TIFA), 2–3
- Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, xvii–xviii. *See also* biotechnology patents; Bolar exception, in TRIPS; compulsory licensing; free trade agreements
- access to medicine and, 24–26
 - anti-competitive conduct under, 259–260
 - Article 31, 60
 - Article 39, 260–263, 390–392
 - Asian approach to, xxi
 - balance of, interpretation of, 389–392
 - Brazil and, 165
 - in Canada, 165
 - compulsory licensing under, 60, 243–252, 402–403
 - data exclusivity and, 260–263
 - EMA and, 390–391
 - EU and, trade disputes under, 165–166
 - exceptions to, 228–238
 - flexibilities under, 58–61, 238–266, 338–339
 - India and, dispute with EU, 165–166
 - international disputes, 165–167
 - IPRs and, xvii–xviii, 58–61
 - Lao PDR and, 42

Cambridge University Press

978-1-107-07273-2 - Trade, Investment, Innovation and their Impact on Access to Medicines:
An Asian Perspective

Locknie Hsu

Index

[More information](#)

458

INDEX

- Trade-Related Aspects (cont.)
 least developed countries (LDCs)
 and, 41–44, 50, 76,
 211–212, 381
 legal obligations in, 164
 NAFTA and, 143, 186–187
 NCEs under, 61
 negotiation options for, 280–281
 the Netherlands and, 165
 objectives of, 227–228
 “Paragraph 6” mechanism,
 Article 31(f) waiver, 60,
 252–254
 parallel imports under, 159–162
 patent bargain and, 71–77, 162–163
 patent law and, 25–26
 patentability under, 238–242
 pharmaceutical industry and, 52–55,
 58–61
 pharmaceutical patents under, 57–58
 principles of, 227–228
 protectionist agenda in developed
 countries and, 81, 82
 public debate over, 81–82
 Public Health Declaration and,
 252–254
 royalty rates in, 394–404
 treaty protections with, 80
 TRIPS-plus provisions, FTAs, 219,
 220–221
 UN Human Rights Council and, 59
 UNAIDS and, 59
 undisclosed information, 57, 74,
 144, 192, 234, 260–262,
 305
 UNDP and, 59
 U.S. and, 165, 167
 WHO and, 59
 WTO and, xvii, 22–23, 164,
 165–167
 traditional medicines
 access to medicine through, 408–409
 in Asia, 21–22
 Transatlantic Trade and Investment
 Partnership (TTIP), 216–217
 Trans-Pacific Partnership (TPP)
 Agreement, 23
 biologics in, 407–408
 FTAs and, 171–172
 treaties, economic. *See also* exception
 provisions, in trade treaties;
 free trade agreements;
 General Agreement on Trade
 and Tariffs; multilateral trade
 and treaties; Trade-Related
 Aspects of Intellectual
 Property Rights Agreement
 coherence among, 339
 interpretation of language in,
 275–277
 negotiation strategies for, 277–281
 for R&D, 366–377
 safe harbours exceptions in, 225–227
 WTO accession protocols in,
 224–225
 TRIPS Agreement. *See* Trade-Related
 Aspects of Intellectual
 Property Rights Agreement
 TRIPS-plus. *See* free trade agreements
 TTIP. *See* Transatlantic Trade and
 Investment Partnership
 tuberculosis, in Asia, 7
 U.K. *See* United Kingdom
 UN Human Rights Council, 59
 UNAIDS. *See* United Nations
 Programme on HIV/AIDS
 undisclosed information, TRIPS
 Agreement, Article 39,
 260–263
 UNDP. *See* United Nations
 Development Programme
 United Kingdom (U.K.)
 *Human Genome Sciences Inc v Eli
 Lilly Company* in, 69–70,
 115, 284
 patentability in, 108, 115
 United Nations Development
 Programme (UNDP), 59
 United Nations Programme on
 HIV/AIDS (UNAIDS), 59
 United States (U.S.)
 BTA and, with Vietnam, 257
 competition law in, 289–294,
 316
 C-Path Initiative in, 348

Cambridge University Press

978-1-107-07273-2 - Trade, Investment, Innovation and their Impact on Access to Medicines:
An Asian Perspective

Locknie Hsu

Index

[More information](#)

INDEX

459

- data exclusivity protection in, 187–188
- Drug Price Competition and Patent Term Restoration Act in, 291
- drug research programmes in, 366
- economic interest in Asia, 2–3
- FTAs and, 173–174, 177–179, 198–200, 220–221
- Hatch-Waxman amendments in, 193
- incentives for innovation in, 343–344
- IPRs in, 220–221
- KORUS FTA, 182–183, 197–198, 226–227
- Medical Innovation Prize Fund Act in, 340
- patentability issues in, 108, 110–111
- Patents for Humanity programme in, 343–344
- pay-for-delay agreements in, 293–294
- Precision Medicine Initiative in, 408
- R&D in, collaborations in, 348
- TIFA and, 2–3
- TRIPS Agreement disputes and, 165, 167
- USSFTA and, 173–174, 177–179, 198–200, 226–227, 262–263, 372
- Universally Cheaper and Quality Medicines Act, 40, 155–156
- U.S.-Singapore Free Trade Agreement (USSFTA), 173–174, 372
 - exception provisions in, 226–227
 - patent linkage provisions in, 198–200, 262–263
 - patent term extensions in, 177–179
 - patentability provisions in, 173–174
- Vienna Convention on the Law of Treaties (VCLT), 231
- Vietnam
 - biotechnology patents in, 125
 - BTA and, with U.S., 257
 - competition law in, 321–322
 - corruption issues in, 88–89
 - drug price controls in, 94
 - IPRs in, 235
 - patentability in, 125
 - pharmaceutical production in, 18
 - procurement agreements in, 89–90
 - regional healthcare systems in, 40
 - TIFAs with, 2–3
- voluntary licensing
 - access to medicine through, 340–342, 433
 - MPP, 339, 340–342, 411
- World Health Organization (WHO), 27–29
 - EML and, 28
 - GSPOA, 335–336
 - HTA advocacy by, 376–377
 - TRIPS and, 59
- World Intellectual Property Organization (WIPO), 59, 357, 360, 419, 432–435, 438
- World Trade Organisation (WTO)
 - accession protocol commitments, 224–225
 - Agreement on Pharmaceutical Products, 393–394
 - China in, 1
 - dispute settlement system, Asian use of, 2
 - disputes, TRIPS and, 22, 146, 164, 165–167, 245–246
 - patent bargain and, 74–76
 - Pharmaceutical Products Agreement for, 393–394
 - procurement agreements, 89–90
 - trilateral study with WHO and WIPO, 432–435
 - TRIPS Agreement and, xvii, 22–23, 164, 165–167
- Zyprexa*, 208